Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Burkitt Lymphoma × veltuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 4 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1 Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 198 Rituximab 102 Etoposide 90 Filgrastim 84 Vincristine 82 Cytarabine 80 Peripheral Blood Stem Cell Transplantation 79 Methotrexate 78 fludarabine phosphate 74 Radiotherapy 63 Prednisone 63 Doxorubicin 62 Dexamethasone 49 Cyclosporine 48 Whole-Body Irradiation 47 Mycophenolic Acid 47 Melphalan 40 fludarabine 38 Busulfan 38 Tacrolimus 35 Antilymphocyte Serum 35 Methylprednisolone 34 blinatumomab 32 merphos 31 Calcium Dobesilate 29 Granulocyte Colony-Stimulating Factor 28 Leucovorin 27 deltacortene 23 Mercaptopurine 23 Carmustine 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡